Resources Antibody Industry Trends Week 2, Apr 2024: Cancer Research Trends at AACR

Week 2, Apr 2024: Cancer Research Trends at AACR

Biointron 2024-04-11 Read time: 4 mins


Here at the AACR (American Association for Cancer Research) Annual Meeting 2024 in San Diego, there are over 7000 abstracts, 300 poster presentations, and 50 symposia all about cancer research. A few topics that are currently trending in the conference include cancer vaccines, AI for diagnostics, novel immunotherapies, and antibody-drug conjugates (ADCs) as a new modality.

  • Cancer Vaccines: The importance of understanding and promoting immunogenicity was emphasized, including several therapeutic cancer vaccines in preclinical and clinical development. For instance, preliminary clinical results of PDC*lung01 in combination with anti-PD-1 in patients with stage IV non-small cell lung cancer (NSCLC) demonstrated a mild safety profile, immunological activity and promising tumor response. This response appeared to be enhanced by the combination with pembrolizumab, a monoclonal IgG4. 

  • AI Diagnostics: At the AACR opening plenary session, Dr. J. Kather discussed artificial intelligence-based biomarkers in cancer histopathology. Cancer histopathology is the study of cancer at a microscopic level, focusing on the examination of tissue samples (biopsies) to analyze the structure, cellular composition, and organization of cancerous tissues. AI can now be used to extract prognostic and predictive data from routine pathology slides, in addition to more challenging biomarker prediction. Possible AI models include foundation models, multimodal models, and large language models. 

  • Novel Immunotherapies: Dr. J. Allison explored historical perspectives, new opportunities, and prospects for cures with immune checkpoint blockade in cancer therapy. Immune checkpoint therapy works by targeting checkpoints and blocking the signals that cancer cells use to evade detection. A common type involves the use of checkpoint inhibitors, which are drugs that block proteins such as PD-1 (programmed cell death protein 1) or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). However, while thousands of patients have benefitted from immune checkpoint therapy, thousands more do not respond to the treatments. Thus, focused research on patient immune responses in the tumor microenvironment is needed to understand this problem. 

  • ADCs: Several antibody-drug conjugates were discussed with highly promising results. From Japan, Daiichi presented, DS-3939a, a novel TA-MUC1-targeting ADC with a DNA topoisomerase I inhibitor DXd, exhibited potent antitumor activity in preclinical models. From Seattle, ProfoundBio’s novel EGFR x cMET bispecific ADC PRO1286 demonstrated broad antitumor activity and promising tolerability in preclinical models. Furthermore, from France, Innate Pharma revealed the preclinical characterizations for IPH45, a novel topoisomerase I inhibitor ADC targeting Nectin4 for the treatment of Nectin-4 expressing tumors. 

Subscribe to our Antibody Industry Trends

Recent Antibody Industry Trends

The start of 2024 has seen leaps in deals for antibody therapeutics, especially ADCs (antibody-drug conjugates). This report aims to explore the events and trends of the biopharmaceutical industry in Q1. As of now, only two novel antibody drugs have been approved this year, but many more in regulatory review are expected to be fully approved.

Image credit: DOI: 10.1038/s41577-021-00542-xThe progress of COVID-19 therapies has seen remarkable strides, particularly in the development and application of antibody-based treatments. Early in the pandemic, the focus was on supportive care, but the rapid advancement in antibody therapies has sign

MAGMA-seq is an integrated technology for antibody wide mutational scanning. DOI:10.1038/s41467-024-48072-zThe use of bioinformatics and computational methods were of high interest in several papers published this past week. Protein language models, akin to natural language processing tools, p

DOI:10.1126/science.adg0564 B cells, or B lymphocytes, are a crucial component of the adaptive immune system andhumoral immunity. They originate from the bone marrow and mature in secondary lymphoid organs, such as the spleen and lymph nodes. The B ce

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.